Back to Careers

Fengling Liu, PhD

linkedin-icon-green

Dr. Fengling Liu joined Juvena as a Director of Protein Science in July 2022. Dr. Liu brings over 10 years of industry experience developing multiple biologics. Since 2010 she served as the Protein Biochemistry lead or group lead of Protein Science in multiple biotechs in the bay area including Medimmune (AstraZeneca), Relypsa, Atreca and Arcus Biosciences.

Her protein science-focused research spanned target identification/confirmation, lead optimization, protein purification and engineering to support vaccine development, small molecule and antibody drug discovery in infectious disease and Immuno-Oncology. She was trained in Biochemistry and Structure Biology during her PhD at Georgia State University. She studied the molecular basis of HIV protease drug resistance through enzyme kinetics and X-ray crystal structures.  She solved over a dozen super high resolution crystal structures of HIV/drug complexes and discovered a novel drug resistance mechanism.

During her postdoc in the lab of Professor Ted Jardetzky in the Structural Biology Department at Stanford Medical School, Dr. Liu studied human viral glycoprotein interactions to discover viral entry inhibitors.

Besides her passion for science and technology, Fengling also enjoys gardening and hiking with family and friends.

Learn more about Fengling

LinkedIn

Back to Careers

Clarence Dunn, PHD

linkedin-icon-green

Clay Dunn joined Juvena Therapeutics in October 2022 as a Principal Scientist on the in vitro drug discovery team.

Clay received a MPH degree in epidemiology from George Washington University where he worked with Andrew Friedman at the Genetic Epidemiology Branch, NCI, on a study characterizing the clinical features of von Hippel Lindau disease. He received his Ph.D. from the University of Washington, where he was trained in epithelial cell biology in the lab of William Carter, Ph.D.. He focused on studying the elements of outside→in signaling mechanisms in both activated and quiescent keratinocyte cell populations.

Clay completed his post-doctoral training in the lab of Paul Lampe, Ph.D. at the Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, WA.. In the Lampe Lab, Clay investigated the biology connecting connexin proteins and Gap Junctional Intercellular Communication (GJIC) to several key cellular functions. His focus was on the kinases and pathways that regulate gap junction function during epidermal wounding and cardiac ischemia.

Clay has spent nearly 10 years in the Bay Area biotech industry developing assays and complex cellular models to support pre-clinical drug development. In five years at Amgen, Clay leveraged high throughput imaging and analysis to conduct IND-enabling studies supporting the development of several assets in Amgen’s pipeline. At Encoded Therapeutics, Clay worked to develop novel bioanalytical assays for the company’s gene therapies, which aim to treat pediatric epileptic seizure syndromes.

 

Learn more about Clarence

PubMed Library

LinkedIn

Back to Careers

Juvena CEO, Hanadie Yousef, PhD, discusses the market opportunity for their unique discovery platform for mapping secreted proteins to unmet medical needs leading to their growing pipeline of biologics for rare and chronic diseases to senior leaders of Mubadala’s LP.

Back to Careers

Senior Program Manager – Preclinical & Platform

Juvena Therapeutics, Inc. is a regenerative medicine biotech startup inviting applicants for Senior Program Manager – Preclinical & Platform who are excited to join a company focused on the discovery and validation of novel disease-modifying biologics that promote tissue regeneration by inducing tissue-specific rejuvenating phenotypes. We are discovering and developing various biologics that can promote disease-modifying phenotypes such as increased stem cell activity, reduced chronic or localized inflammation, reduced fibrosis, improved differentiation, or increased mitochondrial function and metabolism. 

The Senior Program Manager will lead the development, and be the hands-on project manager, of a portfolio of Discovery and Platform projects that are core to Juvena’s mission and strategy. Working with senior leadership and other stakeholders, the successful candidate will lead the development of integrated KPIs, R&D program plans, and portfolio management processes that provide a foundation for driving operational objectives, deliverables, execution, and timelines. They will lead and mentor the company on project management best practices while proactively driving weekly project objectives, identifying and analyzing dependencies, resource planning, determining impact of scenarios with priority changes and pivots on KPIs and milestone objectives, liaising with key stakeholders, and providing key status updates and recommendations to Senior Leadership.

The position is full-time starting as early as possible. This is the perfect opportunity for someone interested in the exciting and fast-paced environment of a startup company and looking to make a difference in human health and health-span.

*Title commensurate with experience

Company Summary

Juvena Therapeutics is a venture backed biotechnology startup discovering and developing disease-modifying biologics by leveraging their computationally-driven discovery platform to rapidly identify and validate secreted proteins with regenerative potential for multiple rare and chronic diseases.

At Juvena Therapeutics, we are on a mission to discover and develop biologics for rare and chronic degenerative diseases by mapping secreted proteins to unmet medical needs through a machine learning (ML)-enhanced platform. Juvena’s approach integrates proteomics, transcriptomics and imaging with phenotypic human in vitro disease model screening and extensive preclinical validation to mine the therapeutic potential of human stem cell secretomes as a rich source of new medicines that promote tissue regeneration and repair. We are advancing lead drug candidates for muscular dystrophies, atrophy, injury, and osteopathies, and establishing new programs targeting tissue-specific degenerative diseases across multiple therapeutic areas. Since our launch in mid-2018, Juvena has discovered and validated several hits for neuromuscular, skeletal, and metabolic diseases. Juvena’ preclinical programs are supported by funding from the National Institute of Health (NIH) and the California Institute of Regenerative Medicine (CIRM). Juvena is advancing a lead program for Myotonic Dystrophy Type 1, a rare autosomal dominant, progressive muscle-wasting disease.

At Juvena we embrace a diversity of backgrounds, experience and approaches that all combine to lead us to world-class scientific results in an inclusive environment.

Position Location and work permit requirement

640 Galveston Dr. Redwood City, 64063

Candidate must be legally authorized to work in the US.

Position Requirements and Duties

  • Working with senior leadership and other stakeholders, lead the establishment of integrated KPIs, R&D program plans, and portfolio management processes that provide a foundation for driving operational objectives, deliverables, execution, and timelines. 
  • Drive program and project management processes & activities such as managing priority, scope, time, cost, risk, and quality while ensuring key company milestones & KPIs are defined and met. Manage meetings, including setting agendas, scheduling, and capturing meeting minutes.
  • Develop and directly manage project portfolio plans for a) the Discovery program through IND-filing for multiple Therapeutic Areas, and for b) the Platform program including Data Science/Bioinformatics/AI-ML projects.
  • Monitor ongoing projects for potential risks and develop proactive mitigation strategies with management and the relevant R&D teams. Identify, track, and support resolution efforts for all program-related issues and effectively communicate to relevant internal and external contractor teams via regular and ad-hoc status updates. 
  • Drive resource planning and impact analysis of priority change/pivot scenarios. Manage changes to project scope, ensuring that all impacts and changes are approved and appropriately communicated.
  • Liaise with external partners such as pharmaceutical companies and critical suppliers.
  • Support the development of TCPs (Target Candidate Profile) and initial TPPs (Target Product Profile).
  • Develop and maintain project/portfolio dashboards, reports, and metrics including timeline GANTTS and status summaries.
  • Lead and mentor the company on project management best practices adoption.
  • Other tasks as assigned.

Qualifications

This position is a great fit if you have/are:

  • Advanced degree + PMP certification (Scientific or Computational focused advanced degree is a plus)
  • 10+ years relevant experience in pharmaceutical drug discovery/development. Experience with biologics development is a plus.
  • 3+ years project management experience in pharmaceutical industry R&D.
  • Track record of advancing R&D projects though Discovery to developmental candidate nomination
  • Experience advancing through preclinical to IND filings a plus
  • ​​Ability to operate in a fast-paced, multi-disciplinary industrial environment.
  • Industry and startup R&D experience is a plus.
  • ​​Strong oral and written communication skills and meeting facilitation skills with the ability to work with others to achieve objectives.

Compensation and Benefits

  • Competitive salary, annual bonus and stock options
  • Health/Dental/Vision insurance
  • Paid vacation and holidays

Apply Now

To apply for this position please complete the form below. Once the form is complete, email your CV and Cover Letter to apply@juvenatherapeutics.com with the title of the position as the subject line.  

This form is currently undergoing maintenance. Please try again later.

Back to Careers

Jyoti Ahlawat, PHD

linkedin-icon-green

Dr. Ahlawat joined Juvena Therapeutics in September 2022 as an Associate Scientist: Drug Discovery. She holds a Master’s degree in Biotechnology from the Indian Institute of Technology, Roorkee (IITR), and a Ph.D. in Chemistry from the University of Texas at El Paso (UTEP). She is a recipient of Academic and Research Excellence award from the College of Science (UTEP). Her dissertation research involved developing materials and testing them in-vitro to develop therapeutics against the gravest of human diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD).

Dr. Ahlawat has published more than 18 articles and book chapters in international, peer-reviewed, reputed journals. She is a recipient of the title “Rising Star in Nanoscience and Nanotechnology” at the 10th IEE International Conference on nanomaterials and applications (IEEE-NAP 2020). She has won Best presentation awards at the Equniox (2022), 26th Annual BioEnvironmental Polymer Society (BEPS-2019), Graduate Expo (2018), and 8th International conference on smart materials, structure, and systems (ISSS-2017). In addition, she has won various travel awards (2018-2020), four research awards (2019-2021), and graduate scholarships (2019-2020). She is an Editorial board member of the Journal Future Trends in Nanotechnology and is serving as a Guest Editor for Science Progress (SAGE Journal).

She has served as Vice president of Graduate Student Assembly (2018), and as President of BioChem graduate student chapter (2021). She recently received honorarium from Society for Science for serving as a Science Talent Search Evaluator in 2021. She received Certificate of Appreciation from the Graduate School for her contribution to Undergraduate Learning in 2021. She has served as science judge for the Sun Country Science & Engineering fair (2021), Regeneron International Science & Engineering fair (2021) and at 2nd annual El Paso STEM expo competition (2019). She worked as an intern for eight months with a medical device company where she participated and led international projects which included renewal and registration of ophthalmic lenses in Mexico, Creating Instructions for Use (IFUs) and technical files, and Translation of IFUs into European languages.

Dr. Ahlawat serves as a peer-reviewer for journals such as Cell Biochemistry and Biophysics, Nanotechnology for Environmental Engineering, Environmental Science, Journal for Drug Delivery, and technology, and Phytotherapy. She delivered four invited scientific talks at International Conferences in 2021-2022.

 

Learn more about Jyoti

LinkedIn

Back to Careers

Horizon Ventures Techcracker conference spotlights Juvena Co-Founder, Hanadie Yousef, PhD as one of 70 founders of innovative new companies developing disruptive technologies that improve lives Oct. 2022

Back to Careers

At the Myotonic Dystrophy Foundation Annual conference Juvena Therapeutics joins a community of advocates, people who suffer from this most common muscular dystrophy, their families, caregivers, clinical leaders and experts, and Industry leaders developing therapeutics for this major unmet medical need Sept. 2022

Back to Careers

Rohit Jadhav, PHD

linkedin-icon-green

Dr. Rohit Jadhav joined Juvena Therapeutics in August 2022, bringing more than 12 years of cross disciplinary experience encompassing the fields of oncology, immune aging and auto-immune  diseases. He has extensive experience in algorithm development for diagnostic and prognostic  biomarker discovery dealing with diverse datasets investigating the Transcriptome, Epigenome and DNA mutations in clinical cohorts.

Dr. Jadhav earned his B.Tech. in Bioinformatics from India, a M.S. in Bioinformatics from Indiana  University, Indianapolis, a PhD in Molecular Medicine from UT Health, San Antonio as a CPRIT  pre-doctoral fellow, followed by a postdoctoral fellowship in Immunology at Stanford School of  Medicine and Mayo Clinic.

Masters & PhD (2009-2016) 

Dr. Jadhav worked on identifying epigenetic biomarkers investigating alterations in DNA  methylation across different cancer types including breast, ovarian, endometrial, oral and  prostate. He was awarded a Cancer Prevention and Research Institute of Texas (CPRIT) Predoctoral Fellowship, which enabled him to be involved in collaborative projects focusing on  non-invasive approaches for biomarker discovery. One such project involved use of single-cell  RNA sequencing to study circulating tumor cells and another involved studying DNA methylation  in cell free DNA, both from peripheral blood. As a lead bioinformatician for these studies, he  implemented classification-based prediction methods to enable identification of a panel of  biomarkers to be used in determining treatment approaches for prostate cancer patients  belonging to different subtypes. These studies have led to 3 approved patents from his mentor  Dr. Tim Huang. During this time, Dr. Jadhav was also a lead author on the study that identified  DNA methylation biomarkers capable of identifying predisposition to breast cancer after prenatal  exposure to the compound bisphenol A and preventive effects of genistein. 

Postdoctoral Fellowship (2017-2022) 

Dr. Jadhav’s work at Stanford University and Mayo Clinic with Dr. Jorg Goronzy who is a leading  expert in immune aging and auto-immunity, focused on epigenetics in the context of chromatin  accessibility and specifically alterations in the immune cell types like CD4 and CD8 T cells during  aging and autoimmune diseases like rheumatoid arthritis. He was also a lead author studying epigenetic alterations in exhausted T-cells post checkpoint blockade therapies in collaboration  with Dr. Rafi Ahmed from Emory University. During this time Dr. Jadhav built pipelines deployed in on-prem clusters and in the cloud for analyzing and visualizing data from RNA-seq, ATAC-seq,  TCR-seq, single cell multiome (RNA+ATAC) , single cell Cite-seq (RNA+Protein) among others.

Dr. Jadhav has published over 30 peer-reviewed papers with over a thousand citations. 

 

Learn more about Rohit

LinkedIn

Back to Careers

Pallavi Kompella, PhD

linkedin-icon-green

Dr. Kompella joined Juvena Therapeutics in July 2022 to support the validation and lead optimization of protein-based therapies in vivo and new mouse model development.

As a trained pharmacologist, Dr. Kompella has extensive experience in contributing to early-stage drug discovery. She has designed and managed several hypothesis-driven mechanistic studies and established preclinical mouse models for lead optimization and toxicological risk assessment of potential small molecule drugs across several therapeutic areas.

After receiving her Bachelor’s and Master’s degree in Biotechnology from India, she worked for 8 years at various drug discovery organizations in India and the U.S. Dr. Kompella received her Ph.D. in Pharmacology and Toxicology from the University of Texas at Austin (UT Austin) where she investigated the underlying molecular mechanisms of how diet-induced obesity influences DNA damage and repair and contributes to cancer development. Dr. Kompella has been awarded multiple graduate fellowships from UT Austin and the American College of Toxicology. She is also the recipient of an American Foundation for Pharmaceutical Education (AFPE) pre-doctoral research fellowship. 

Before joining Juvena Therapeutics, Dr. Kompella was a Fulbright U.S. Postdoctoral Scholar at the Biomedical Research Institute of Malaga (IBIMA) in Malaga Spain. At IBIMA, she studied the role of obesity-mediated epigenetic modification of DNA damage repair protein OGG1 in visceral adipose tissue from patients with obesity.


Besides research, she loves doing science outreach and going on hikes with friends and family.

Learn more about Pallavi

LinkedIn

Back to Careers

Senior Computational Biologist – Proteomics

Position Description

Juvena Therapeutics, Inc. is a regenerative medicine biotech startup inviting applicants for Computational Biologist – Proteomics who are excited to work as a core member of a team focused on the discovery and validation of novel candidate biologics for tissue regeneration and increased stem cell activity.

The senior computational biologist will be responsible for driving lead biologics and biomarker discovery and prioritization from proteomics and multi-omics experiments by using their deep understanding of protein identification, quantitation,  and characterization, extracting meaningful biological insights from large, complex omics datasets (such as interaction networks, molecular single cell resolution studies, expression profiling), and integrating the results into Juvena Therapeutics’ growing in-house knowledge ecosystem. Expertise in protein modeling for computational chemistry/drug discovery would be considered equal to and in place of multi-omics analysis experience.

They will develop and apply creative, leading-edge approaches in bioinformatics, biostatistics, and machine-learning to identify novel biologics and enhance the efficiency of lead therapeutic drug screening and design. They will also support all stages of drug development that require proteomics applications and/or computational biology/bioinformatics.

The position is full-time starting as early as possible. This is the perfect opportunity for someone interested in the exciting and fast-paced environment of a startup company looking to make a difference in human health and healthspan.

Company Summary

Juvena Therapeutics is a venture backed biotechnology startup discovering and developing disease-modifying biologics by leveraging their computationally-driven discovery platform to rapidly identify and validate secreted proteins with regenerative potential for multiple rare and chronic diseases.

At Juvena Therapeutics, we are on a mission to discover and develop biologics for rare and chronic degenerative diseases by mapping secreted proteins to unmet medical needs through a machine learning (ML)-enhanced platform. Juvena’s approach integrates proteomics, transcriptomics and imaging with phenotypic human in vitro disease model screening and extensive preclinical validation to mine the therapeutic potential of human stem cell secretomes as a rich source of new medicines that promote tissue regeneration and repair. We are advancing lead drug candidates for muscular dystrophies, atrophy, injury, and osteopathies, and establishing new programs targeting tissue-specific degenerative diseases across multiple therapeutic areas. Since our launch in mid-2018, Juvena has discovered and validated several hits for neuromuscular, skeletal, and metabolic diseases. Juvena’ preclinical programs are supported by funding from the National Institute of Health (NIH) and the California Institute of Regenerative Medicine (CIRM). Juvena is advancing a lead program for Myotonic Dystrophy Type 1, a rare autosomal dominant, progressive muscle-wasting disease.

At Juvena we embrace a diversity of backgrounds, experience and approaches that all combine to lead us to world-class scientific results in an inclusive environment.

Position Location and work permit requirement

640 Galveston Dr. Redwood City, 64063

Candidate must be legally authorized to work in the US.

Major Responsibilities

  • Bring to the Discovery team your expertise in:
    • Design and analysis of data-dependent acquisition  and data-independent acquisition proteomics experiments (mass-spec based required)
    • Analysis of isobaric labeling proteomics data
  • Integrate analysis of multi-omics and interaction network data or computational protein/drug discovery modeling
  • Reference and re-analyze existing proteomics datasets
  • Develop and apply machine learning methods to enhance the efficiency of candidate biologics discovery and screening for increased stem cell activity.
  • Work cross-functionally to create the best possible pipeline of candidate therapeutics and the tools to scale out efficiently across multiple indications. 
  • Improve efficiency by automating data extractions, analyses, and reporting; 
  • Other scientific tasks as required.
  • Actively survey the forefront of published methods and resources for your field and internalize key aspects to the company

Position Requirements and Experience

This position is a great fit if you have/are:

  • Ph.D. in bioinformatics, biology, biochemistry or analytical chemistry with 5+ years relevant experience in mass spectrometry-based proteomics 
  • Broad knowledge of mass spectrometry-based protein quantification and characterization strategies & analysis tools
  • Demonstrated mastery of bioinformatics/proteomics/multi-omics analysis with publications, co-inventorships, or other impressive achievements
  • Highly communicative. Effective communicator verbally, in writing, and in presentations to both expert and novice audiences
  • Self-Starter – Can work independently and/or collaboratively with scientists to make appropriate and timely decisions to meet deadlines on experiments and projects
  • Strong foundational knowledge and experience with biological data, particularly with methods generating large scale omics data sets (e.g. epigenomics, genomics, transcriptomics, proteomics)
  • Demonstrated expertise in an analysis and automation language (e.g. Python, R)
  • Demonstrated expertise in cloud computing systems – experience with Google Cloud and AWS resources is a plus
  • Familiarity with pharmaceutical R&D is a plus.
  • Industry or startup R&D experience is a plus.

Compensation and Benefits

  • Competitive salary, annual bonus and stock options
  • Health/Dental/Vision insurance
  • Paid vacation and holidays

Apply Now

To apply for this position please complete the form below. Once the form is complete, email your CV and Cover Letter to apply@juvenatherapeutics.com with the title of the position as the subject line.  

This form is currently undergoing maintenance. Please try again later.